EDOC Global X Telemedicine ETF NASDAQ $9.45 19 Feb 2026: Oversold bounce, 11.02 USD

EDOC stock trades at $9.45 in pre-market on NASDAQ on 19 Feb 2026, setting up a potential oversold bounce after sliding below both the 50-day and 200-day averages. The Global X Telemedicine & Digital Health ETF has low intraday liquidity with volume 9,067 versus an average of 27,022, and a one-year range of $8.16–$11.91. For short-term traders, this gap below the 50-day mean is the key trigger for a bounce strategy. We review fundamentals, technicals, sector context, and Meyka AI’s model forecast to frame realistic entry, stops, and targets for pre-market trading.

EDOC stock pre-market snapshot

EDOC stock is quoted at $9.45 pre-market on NASDAQ in the United States, up 0.07 (0.75%) from the prior close of $9.38. Day range is $9.22–$9.45, year high $11.91, year low $8.16, market cap $35,124,185, and shares outstanding 3,716,845. Volume of 9,067 is low versus an average of 27,022, which raises liquidity risk for larger orders.

EDOC stock technicals and oversold signals

Price sits below the 50-day average ($10.26) and the 200-day average ($9.79), a classic setup for an oversold bounce attempt. Short-term volatility is moderate with ATR $0.18 and Keltner channels centered at $9.47 (middle), suggesting near-term mean reversion to the $9.47–$10.26 band. Traders should note the thin volume and the day low $9.22 as immediate support.

EDOC stock fundamentals and valuation

As an ETF, the Global X Telemedicine & Digital Health ETF (EDOC) provides sector exposure rather than company-level cash flows, but listed metrics still matter for trading. Reported EPS proxy is 0.25 with a fund-level PE shown as 38.48, dividend per share $0.08, and dividend yield about 0.85%. The fund is passive and non-diversified, which concentrates sector and security risk in telemedicine and digital health names.

Meyka AI rates EDOC with a score out of 100

Meyka AI rates EDOC with a score out of 100: 63.68 (Grade B — Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. The grade reflects moderate opportunity with material sector and liquidity risks; these grades are informational and not financial advice.

EDOC stock forecast and price targets

Meyka AI’s forecast model projects a 12-month level near $11.02, implying an upside of approximately 16.62% from the current $9.45. Short-term technical targets for an oversold bounce are the 50-day average $10.26 and the 200-day average $9.79, with a conservative 12-month target aligned to the model at $11.02. Forecasts are model-based projections and not guarantees.

EDOC stock risks and trading opportunities

Primary risks include low liquidity, concentrated sector exposure, and sensitivity to telehealth sector headlines and regulation. Opportunity exists if sector flows rotate back into healthtech and larger names in the ETF regain momentum, creating a short-term bounce toward the 50-day average. For context and fund detail see Investing.com EDOC page and our coverage on Meyka AI’s platform at EDOC on Meyka.

Final Thoughts

EDOC stock is a pre-market oversold bounce candidate at $9.45 on NASDAQ on 19 Feb 2026, trading below both the 50-day ($10.26) and 200-day ($9.79) averages. Low intraday volume and the fund’s concentrated telemedicine exposure increase risk for long positions, but the technical setup supports a mean-reversion trade to the $10.26 level and beyond toward Meyka AI’s 12-month forecast of $11.02. That forecast implies about 16.62% upside from current levels but comes with clear caveats: model-based projections are not guarantees. Meyka AI’s grade of 63.68 (B, HOLD) signals moderation — the ETF is suitable for tactical traders who manage size and stop-losses, and for diversified investors as a thematic satellite exposure rather than a core holding. For pre-market entries, consider scaling in near $9.30–$9.50, protect with a stop under the year low at $8.16, and target the 50-day and the model forecast levels. Meyka AI provides this AI-powered market analysis to frame trades and longer-term outlooks, not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.